Today's Pharma Pulse
Global drugmakers accelerate U.S. manufacturing and R&D amid looming 100% tariff threat
Pharmaceutical giants are boosting U.S. production and research investments as the Trump administration threatens 100% tariffs on branded drugs unless prices are cut or production moves domestically. Companies including Pfizer, AstraZeneca, Eli Lilly, Johnson & Johnson and Roche have pledged commitments ranging from $3.5 billion to $70 billion to secure temporary tariff exemptions.
Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes
A phase 3 trial (ACHIEVE‑5) showed that adding the oral GLP‑1 agonist orforglipron to titrated insulin glargine significantly lowered HbA1c in adults with type 2 diabetes, with reductions ranging from 0.78 % to 1.08 % versus placebo. Across three dose levels, participants also lost 2.7 %‑6.1 % of body weight, reversing the typical weight gain seen with basal insulin. Fasting glucose fell and insulin glargine doses were modestly reduced, indicating improved glycemic control without extra insulin. The safety profile was consistent with the GLP‑1 class, with mainly mild gastrointestinal events.
STAT+: AstraZeneca’s GLP-1 Pill Shows Promise in Obesity, Diabetes Trials
AstraZeneca’s experimental oral GLP‑1 drug elecoglipron delivered notable results in two Phase 2 studies. In the VISTA obesity trial, participants on the top dose lost an average of 11.2% of body weight over 36 weeks. In the SOLSTICE diabetes trial, the same...
Wegovy Pill Hits 3 Million U.S. Prescriptions, One Filled Every Five Seconds
Novo Nordisk announced that Wegovy® tablets have surpassed three million prescriptions in the United States within just over five months, averaging one fill every five seconds. The surge reflects strong demand from patients new to GLP‑1 therapy and positions Wegovy...
Mirvetuximab Soravtansine and the Growing Importance of Precision Oncology Education
The NHS has approved mirvetuximab soravtansine, an antibody‑drug conjugate, for patients with folate receptor‑alpha‑positive, platinum‑resistant ovarian cancer. This marks the first biomarker‑directed therapy for this hard‑to‑treat subgroup in England, offering a new line of treatment after two decades of limited...
Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration
Roche has signed an exclusive global licensing deal with Nurix Therapeutics, providing $700 million upfront and up to $2.3 billion in milestone payments to co‑develop and co‑commercialize bexobrutideg, an oral BTK degrader, across oncology, immunology and neurology. The molecule, which degrades rather...
Janus Kinase (JAK) Inhibitors: Drug Safety Communication - FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood...
The FDA is mandating updated Boxed Warnings for the JAK inhibitors Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to highlight elevated risks of serious heart events, cancer, blood clots, and death. The directive follows a large randomized safety trial that found Xeljanz...
City Therapeutics Builds RNAi Pipeline with $99.5M Series B
City Therapeutics announced a $99.5 million Series B financing to accelerate its RNA‑interference pipeline. The round backs its lead candidate CITY‑FXI, a Factor XI inhibitor in Phase 1 aimed at preventing clots without increasing bleed risk. Funds will also support a next‑generation trigger‑molecule platform...
Chikungunya Vaccine Development in Africa Accelerated by ACT-CHIK
Institut Pasteur has launched ACT-CHIK, a four‑year, EU‑funded programme to fast‑track a measles‑virus‑based chikungunya vaccine (MV‑CHIK) in Africa. The project, backed by €15.3 million (about $16.7 million) from the Horizon Europe EDCTP3 fund, will run a Phase Ib/III trial enrolling 940 participants across...
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
A recent narrative review in Frontiers in Immunology finds that GLP‑1 receptor agonists such as liraglutide and semaglutide improve psoriasis severity and systemic inflammation, independent of weight loss. Evidence in psoriatic arthritis (PsA) remains limited to a single small study,...
BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
The FDA released interim and final assessments of its Program for Enhanced Review Transparency and Communication under the reauthorized Biosimilar User Fee Act (BsUFA II). The initiative adds structured communication windows and extra review clock time for biosimilar biologics license applications...
Ultrasound Converts Anticancer Drug Into Potent Anti‑pneumonia Agent
Ultrasound switched the anticancer molecule TLD1433 into a bacteria-killing agent for deep, oxygen-poor lung infections. The approach boosted reactive oxygen species and worked in antibiotic-resistant pneumonia models. science
Petrelintide Induces 10% Weight Loss, High Tolerability
Petrelintide, a long‑acting human amylin analog, demonstrated up to 10.7% weight loss over 42 weeks in the phase 2 ZUPREME‑1 trial involving 493 adults with obesity. The once‑weekly injection showed a safety profile comparable to placebo, with overall adverse events in...
CagriSema Reduces HbA1c, Weight in Adults with Type 2 Diabetes
Novo Nordisk’s once‑weekly combo CagriSema, pairing cagrilintide with semaglutide, demonstrated significant HbA1c and weight reductions in three phase 3 REIMAGINE trials covering treatment‑naïve, metformin/SGLT2‑treated, and basal‑insulin patients. In REIMAGINE 1, the 2.4 mg dose lowered HbA1c by 1.8 percentage points and cut weight by...
J&J Glows with $1B Buyout of Firefly and Its Degrader Platform Tech
Johnson & Johnson announced a $1 billion cash acquisition of California‑based Firefly Bio, securing its degrader antibody conjugate (DAC) platform. The technology merges antibody‑drug conjugate precision with protein‑degrader capability to target KRAS‑driven solid tumors, a class long deemed undruggable. Firefly, founded...
Teva Shows Positive Real‑World Evidence for AUSTEDO & AUSTEDO XR in Huntington’s Chorea
Teva Pharmaceutical announced positive real‑world evidence for its VMVM2 inhibitors AUSTEDO and AUSTEDO XR in treating Huntington’s chorea, presented at the 2026 Advanced Therapeutics in Movement & Related Disorders congress. The data, drawn from routine clinical practice, suggest the drugs...
MannKind Shows Pediatric Safety for Afrezza at ADA 2026, Expanding Needle‑Free Insulin Use
MannKind Corp. unveiled clinical and real‑world data on its inhaled insulin Afrezza at the American Diabetes Association’s 2026 Scientific Sessions, confirming safety for pediatric patients aged six and older. The findings follow the FDA’s recent approval of Afrezza for children...
Novo Nordisk Backs Veru’s Obesity Drug Trial, Securing First‑refusal Rights
Novo Nordisk has agreed to provide Wegovy free of charge for Veru’s Phase 2b PLATEAU trial and secured a right of first negotiation on any future development of Veru’s oral enobosarm. The deal gives the Danish giant a foothold in next‑generation...
Regulatory Actions for June 8, 2026
On June 8 2026 regulators released a batch of biopharma and med‑tech actions, covering global submissions, approvals and special designations. The snapshot highlighted three companies—Chiesi, Lupin and Tandem—each receiving distinct regulatory outcomes. While details vary by product line, the announcements signal active...
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
Ignite Proteomics, a subsidiary of Aditxt, announced a prospective oncology registry that will enroll up to 10,000 patients to pair its CLIA‑certified Reverse Phase Protein Array (RPPA) platform with structured outcomes tracking. The registry will focus on patients receiving antibody‑drug...
A Drug May Help People on GLP-1 Meds Preserve Muscle
A proof‑of‑concept study published in Nature Medicine shows that the experimental myostatin‑blocking antibody apitegromab can halve lean‑mass loss in patients taking tirzepatide, a GLP‑1 weight‑loss drug. In a 24‑week trial of 102 overweight or obese adults, both groups lost similar...
Ensuring Quality and Access: FDA’s Approach to Generic Drug Oversight
The FDA’s generic drug program recently cleared major milestones, approving the first generic complex inhalers (Flovent, QVAR) and a GLP‑1 receptor agonist (Saxenda). On May 21, 2026 the agency released product‑specific guidances that trim costly clinical study requirements for inhalation generics, aiming...
STAT+: Novo Underwhelmed by Drug It Once Fought Pfizer For
Novo Nordisk is downplaying an obesity drug it once contested with Pfizer, signaling a shift in its confidence about the product’s market potential. The drug, previously seen as a flagship GLP‑1 therapy, now faces stiff competition from emerging rivals. Meanwhile,...
How AI Is Unlocking Smarter Clinical Trial Protocols
Artificial intelligence is reshaping clinical trial protocols, shifting from static, paper‑based documents to digital, data‑driven frameworks. The Tufts Center reports that 76% of trials require at least one major amendment, adding months and costly delays. By fine‑tuning domain‑specific AI models...
Dayspring Pharma Announces Phase II Success for CG2001 Hair‑Loss Treatment
Dayspring Pharma disclosed topline Phase II data for its topical minoxidil‑finasteride combo CG2001, reporting a 28.17 hairs/cm² increase in target‑area hair count versus 7.68 for placebo. The results, presented at the World Congress for Hair Research in Seoul, position the...
Gilead Completes $500M Ouro Deal, Giving Lakefront $500M for Independent M&A
Gilead Sciences finalized a $500 million purchase of Lakefront Biotherapeutics' Ouro inflammation platform on June 4, 2026. The transaction grants Lakefront at least $500 million of free cash and earmarks $150 million for share buybacks, while preserving a co‑development partnership on the experimental drug...
Everest Medicines Secures Greater China Rights to VIZZ Eye‑Drop for Presbyopia
Everest Medicines (HKEX:1952) has taken over the rights to develop, manufacture and sell VIZZ, the first US‑approved aceclidine eye drop for presbyopia, across mainland China, Hong Kong, Macau and Taiwan. The deal transfers obligations from Corxel Pharmaceuticals and promises LENZ...
IMMX's NXC-201 Shows 95
We have been fans of $IMMX for some time, and the recent selloff is creating what looks like an interesting opportunity in what may be one of the more disruptive cell therapy platforms in development. • NXC-201 has reported a...
First Prenatal Gene Therapy Trial Targets GM1 Disorder
Researchers at the University of California, San Francisco have launched a first-in-human prenatal gene therapy trial for GM1 gangliosidosis, aiming to treat the disease before birth and potentially open the door to fetal gene therapies for a wide range of...
OriCell’s GPC3‑Targeted CAR‑T Ori‑C101 Clears NMPA for Phase II Liver Cancer Trial
OriCell Therapeutics announced that its GPC3‑directed autologous CAR‑T, Ori‑C101, has been cleared by China’s National Medical Products Administration to enter a confirmatory Phase II randomised trial in patients with advanced hepatocellular carcinoma who have failed two or more prior therapies. The...
J&J to Buy Firefly, Securing Degrader Antibody Platform
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B https://t.co/7LR42oP7kZ by @gwendolynawu #biotech $JNJ
Daraxon
Follow up on the $TNGX data from this morning. Cross-trial comparison caveats.... Daraxonrasib ORR results from the RASolute302 study: https://t.co/MJsD6KWPIi
Module 4 Quiz
Drug Hunter has released a Module 4 quiz covering its Protein Structure & Target Pharmacology course. The assessment tests learners on every section of the module, reinforcing concepts essential for drug discovery. Access to the quiz requires a paid subscription, which...
Approved Drugs: Questions and Answers
The FDA approves new medicines after a multi‑stage evaluation that begins with laboratory and animal studies, proceeds through phased human clinical trials, and culminates in a comprehensive data review by the Center for Drug Evaluation and Research (CDER). CDER scientists...
Psychedelic Therapy Standardized for Clinical Depression Shows Massive Promise in Pilot Trial
UCLA researchers piloted a four‑month program that paired two psilocybin doses (10 mg then 25 mg) with twelve one‑hour cognitive‑behavioral therapy sessions for 16 adults with major depressive disorder. Thirteen participants showed moderate‑to‑large reductions in standardized depression scores, and nine achieved full...
STAT+: Combination of Pancreatic Cancer Drugs From Tango, Revolution Leads to High Response Rate
Revolution Medicines' KRAS G12C inhibitor daraxonrasib, already highlighted for pancreatic cancer, was paired with Tango Therapeutics' epigenetic drug vopimetostat in a new study. The early‑stage trial reported durable responses in the large majority of participants, with significant tumor reductions observed....
Lawmakers Warn Against Weakening IP for Medicines in House Hearing
Lawmakers on the House Judiciary Subcommittee defended strong patent protections as essential to U.S. biotech innovation during a June 4 hearing, coinciding with a Supreme Court decision that a generic maker did not infringe patents in the Hikma case. Speakers...
GLP‑1/GIP Therapies Deliver Double‑Digit Weight Loss in Phase 3 Trials
Eli Lilly's retatrutide, Novo Nordisk's CagriSema, Lilly's oral Foundayo and Hengrui/Kailera's ribupatide all posted Phase 3 or late‑stage results showing double‑digit weight loss and significant blood‑sugar reductions, positioning multi‑hormone GLP‑1 therapies as potential game‑changers for obesity and type‑2 diabetes.
Survodutide Cuts Liver Fat by 30% in 84% of Patients, Triggers 12% Weight Loss in Phase 3 Trial
In the SYNCHRONIZE-MASLD phase 3 trial, survodutide achieved a ≥30% reduction in liver fat in 84.2% of treated patients versus 24.3% on placebo, and produced an average 12.2% body‑weight loss versus 1.0% for placebo. The results position the GLP‑1/glucagon dual agonist...
F2G’s Global Strategy for Rare Fungal Infection Trials
F2G is advancing olorofim, a first‑in‑class orotomide antifungal, toward Phase III data expected in mid‑June 2026. The drug targets invasive aspergillosis, rare mold infections and Valley fever, showing a drop in three‑month mortality from ~90% to 27% in a Phase IIb study of...
EU Approves Sanofi’s Sarclisa SC, First On‑Body Injector for Multiple Myeloma
Sanofi announced that the European Commission has approved Sarclisa (isatuximab) subcutaneous, administered via an on‑body injector, for all existing multiple myeloma indications. The approval makes Sarclisa SC the first anticancer therapy in the EU delivered through an on‑body injector, offering...
Amgen Unveils VESALIUS‑CV Subgroup Data on Evolocumab for High‑Risk Diabetic Patients
Amgen announced new subgroup analyses from its phase 3 VESALIUS‑CV trial, focusing on Evolocumab’s performance in high‑risk diabetes patients with elevated LDL‑C who have not experienced a prior heart attack or stroke. The data, presented without detailed numbers, could broaden...
Roche, Nurix Seal $2.3 Bn Deal to Co‑develop BTK Degrader Bexobrutideg
Roche and Nurix Therapeutics have signed an exclusive licensing and collaboration agreement worth up to $2.3 bn to co‑develop and co‑commercialise the BTK degrader bexobrutideg (NX‑5948). The deal includes a $700 m upfront payment and a 60/40 split of development costs, positioning...
EnGene Therapeutics: The Selloff Creates An Opportunity
enGene Therapeutics (ENGN) shares plunged 80% after weak Phase 2 interim data for its sole product detalimogene voraplasmid, which showed only a 25% 12‑month complete response rate. Despite the low efficacy, the drug maintains a strong safety profile and Fast Track/RMAT...
Next-Gen Oligonucleotides to Transform Patient Care
Secarna Pharmaceuticals is leveraging its AI‑powered OligoCreator® platform to accelerate the design of antisense and siRNA therapeutics, with a focus on hard‑to‑treat cancers. The company’s lead asset, SECN‑15, is a high‑affinity antisense oligonucleotide that down‑regulates NRP1, a protein linked to...
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Innovent Biologics unveiled a suite of next‑generation obesity and metabolic candidates at the 2026 ADA Scientific Sessions, including oral GLP‑1 receptor agonists IBI3032 (daily) and IBI3042 (weekly), a novel amylin analog IBI3040, and an INHBE‑targeting siRNA IBI3046. Preclinical studies showed...
Opinion: $2 Million Gene Therapy Cures Require a Financing Model
Gene therapies that can cure diseases like sickle cell are priced at $2 million per patient, concentrating decades of health value into a single intervention. While the clinical benefits are clear, the U.S. health‑care system lacks mechanisms to fund such large...
Eli Lilly’s Retatrutide Delivers Significant Improvements in Weight, A1C, Knee Osteoarthritis Pain, and Obstructive Sleep Apnea (OSA)
Eli Lilly’s triple‑agonist retatrutide delivered robust outcomes in two Phase 3 studies. In the TRIUMPH‑1 obesity trial, participants lost up to 28.3% of body weight, with a 85‑lb reduction in those starting with a BMI ≥ 35, while also cutting knee‑osteoarthritis pain by roughly...
Novo Nordisk Reports Phase II Data for Zenagamtide in Diabetes
Novo Nordisk announced that its investigational drug zenagamtide met all primary and key secondary endpoints in a Phase II trial in adults with type 2 diabetes, delivering up to a 1.71% HbA1c reduction and 14.6% weight loss at the 40 mg dose. The...
EC Grants Marketing Authorisation for IntraBio’s Aqneursa
The European Commission has granted marketing authorisation for IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms of Niemann‑Pick disease type C across the EU. The drug is approved for patients six years and older weighing at least 20 kg, either alone or with...
Rethinking Insulin Resistance in Aging: A Reserve-Oriented Clinical Framework (Paper July 2026)
A new reserve‑oriented framework redefines insulin resistance in older adults, emphasizing muscle quality, mitochondrial health, and functional biomarkers over simple weight loss. The paper outlines actionable interventions—including SGLT2 inhibitors, senolytic fisetin, intranasal insulin, nicotinamide riboside, and weekly semaglutide—each supported by...